Different cancer cells have varying dependencies on fuels like glutamine and glucose. By targeting both fuel sources simultaneously, it is possible to effectively kill all cancer cells, as the cells cannot shift to alternative fuels. While the pharmaceutical industry is developing glutamine targeting drugs, many are not specific enough to be effective. Despite using a 'dirty drug' that lacks specificity to block all pathways for glutamine metabolism, the priority remains extending patients' lives over profit.
Thomas Seyfried, PhD is a preeminent cancer expert and professor in the department of biology at Boston College. He received a PhD in 1976 in genetics and neurochemistry from the University of Illinois at Urbana-Champaign, followed by a postdoctoral degree from Yale University in the field of neurochemistry and genetics.
Become a Genius Life Premium Member and get ad-free episodes of the show, a monthly Ask Me Anything (AMA), and more! Learn more: http://thegeniuslife.com